A Case of Chronic Hepatitis B in which HBs Antigen Seroclearance was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up-Reference-Cited by-同舟云学术

A Case of Chronic Hepatitis B in which HBs Antigen Seroclearance was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Mimura Shima¹,Ono Masafumi¹,Fujita Koji¹,Takuma Kei¹,Nakahara Mai¹,Oura Kyoko¹,Tadokoro Tomoko¹,Tani Joji¹,Morishita Asahiro¹,Kagawa Seiko²,Okano Keiichi³,Himoto Takashi⁴,Masaki Tsutomu¹

Affiliation:

1. Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan

2. Department of Pathology, Faculty of Medicine, Kagawa University, Japan

3. Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Japan

4. Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3643-24/_pdf

Reference30 articles.

1. 1. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1012, 2011.

2. 2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.

3. 3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73, 2006.

4. 4. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142: 1140-1149, 2012.

5. 5. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, et al. Long-term monitoring shows hepatitis b virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 49: 1503-1514, 2009.